PL2603528T3 - Przeciwciała Fab-glikozylowane - Google Patents

Przeciwciała Fab-glikozylowane

Info

Publication number: PL2603528T3
Authority: PL; Poland
Prior art keywords: fab; glycosylated antibodies; glycosylated; antibodies
Prior art date: 2010-08-10

Application number

PL11760415T

Other languages

English (en)

Inventor

Steffen Goletz

Antje Danielczyk

Lars Stoeckl

Original Assignee

Glycotope Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-10

Filing date

2011-08-10

Publication date

2017-07-31

2011-08-10 Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh

2017-07-31 Publication of PL2603528T3 publication Critical patent/PL2603528T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL11760415T 2010-08-10 2011-08-10 Przeciwciała Fab-glikozylowane PL2603528T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2010004878		2010-08-10
EP11760415.7A EP2603528B1 (en)	2010-08-10	2011-08-10	Fab-glycosylated antibodies

Publications (1)

Publication Number	Publication Date
PL2603528T3 true PL2603528T3 (pl)	2017-07-31

Family

ID=44674756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11760415T PL2603528T3 (pl)	2010-08-10	2011-08-10	Przeciwciała Fab-glikozylowane

Country Status (12)

Country	Link
US (1)	US9359439B2 (pl)
EP (1)	EP2603528B1 (pl)
JP (2)	JP6334166B2 (pl)
CN (1)	CN103119064B (pl)
AU (1)	AU2011288464B2 (pl)
BR (1)	BR112013003095B1 (pl)
CA (1)	CA2805984C (pl)
DK (1)	DK2603528T3 (pl)
ES (1)	ES2605304T3 (pl)
PL (1)	PL2603528T3 (pl)
PT (1)	PT2603528T (pl)
WO (1)	WO2012020065A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9051370B2 (en)	2010-08-10	2015-06-09	Glycotope Gmbh	Humanized EGFR antibodies
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
SG10201809779RA (en)	2013-03-11	2018-12-28	Genzyme Corp	Site-specific antibody-drug conjugation through glycoengineering
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
KR20150144804A (ko) *	2013-04-22	2015-12-28	글리코토페 게엠베하	낮은 푸코실화를 갖는 항ｅｇｆｒ 항체를 이용한 항암 치료
HRP20230260T1 (hr)	2014-03-19	2023-04-28	Genzyme Corporation	Glikoinženjering ciljajućih dijelova specifičan za mjesto
WO2016037947A1 (en) *	2014-09-10	2016-03-17	F. Hoffmann-La Roche Ag	Galactoengineered immunoglobulin 1 antibodies
ES2804826T3 (es) *	2014-09-16	2021-02-09	Synermore Biologics Co Ltd	Anticuerpo anti-EGFR y usos del mismo
CA3205824A1 (en)	2014-10-09	2016-04-14	Genzyme Corporation	Glycoengineered antibody drug conjugates
WO2016150845A1 (en) *	2015-03-20	2016-09-29	Ablynx Nv	Glycosylated immunoglobulin single variable domains
WO2017162733A1 (en) *	2016-03-22	2017-09-28	Glycotope Gmbh	Iga antibodies with enhanced stability
CN110352074B (zh)	2017-02-28	2024-07-16	思进股份有限公司	用于偶联的半胱氨酸突变抗体
EP3707167A4 (en) *	2017-11-09	2021-08-04	National Research Council of Canada	ANTIBODY GLYCOCONJUGATES AND METHOD OF MANUFACTURING AND USE
TW202402806A (zh)	2018-05-18	2024-01-16	日商第一三共股份有限公司	抗muc1抗體藥物複合體

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB9200415D0 (en) *	1992-01-09	1992-02-26	Bagshawe Kenneth D	Inactivation of cytotoxic drugs
US5443953A (en) *	1993-12-08	1995-08-22	Immunomedics, Inc.	Preparation and use of immunoconjugates
CA2222231A1 (en)	1995-06-07	1996-12-19	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth of tumors
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
EP1432444A4 (en) *	2001-08-17	2005-11-02	Lilly Co Eli	ANTI-BETA ANTIBODIES
WO2003074679A2 (en)	2002-03-01	2003-09-12	Xencor	Antibody optimization
DE10303664A1 (de)	2003-01-23	2004-08-12	Nemod Immuntherapie Ag	Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
AU2004264265C1 (en) *	2003-08-14	2012-06-28	Thrombogenics Nv	Antibodies against factor VIII with modified glycosylation in the variable region
DK1654353T3 (da)	2003-08-18	2013-08-26	Glycotope Gmbh	Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
EP1725673A1 (en)	2004-02-13	2006-11-29	Glycotope Gmbh	Sialytated glycoproteins-process conditions and an efficient method for their production
US20060051353A1 (en) *	2004-05-14	2006-03-09	Jean-Frederic Colombel	Methods and compositions to evaluate antibody treatment response
MX2007014148A (es) *	2005-05-19	2008-01-11	Amgen Inc	Composiciones y metodos para incrementar la estabilidad de anticuerpos.
PT1896071E (pt) *	2005-06-30	2015-07-09	Janssen Biotech Inc	Métodos e composições com melhorias na atividade terapêutica
GB0519398D0 (en) *	2005-09-23	2005-11-02	Antisoma Plc	Biological materials and uses thereof
US20090181016A1 (en) *	2005-11-30	2009-07-16	University Of Southern California	FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
EP2428224B1 (en) *	2006-09-10	2016-12-21	Glycotope GmbH	Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008101177A2 (en) *	2007-02-16	2008-08-21	University Of Virginia Patent Foundation	Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
JP5628790B2 (ja) *	2008-04-07	2014-11-19	バイエル・ヘルスケア・エルエルシー	糖タンパク質の組換え生産の方法
PE20100054A1 (es)	2008-06-03	2010-03-03	Abbott Lab	Inmunoglobulina con dominio variable dual
EP2281844A1 (en)	2009-07-31	2011-02-09	Glycotope GmbH	MUC 1 antibodies
US9051370B2 (en) *	2010-08-10	2015-06-09	Glycotope Gmbh	Humanized EGFR antibodies

2011
- 2011-08-10 CN CN201180039635.7A patent/CN103119064B/zh active Active
- 2011-08-10 WO PCT/EP2011/063791 patent/WO2012020065A1/en active Application Filing
- 2011-08-10 ES ES11760415.7T patent/ES2605304T3/es active Active
- 2011-08-10 PT PT117604157T patent/PT2603528T/pt unknown
- 2011-08-10 JP JP2013523612A patent/JP6334166B2/ja active Active
- 2011-08-10 DK DK11760415.7T patent/DK2603528T3/en active
- 2011-08-10 EP EP11760415.7A patent/EP2603528B1/en active Active
- 2011-08-10 AU AU2011288464A patent/AU2011288464B2/en active Active
- 2011-08-10 BR BR112013003095-0A patent/BR112013003095B1/pt active IP Right Grant
- 2011-08-10 CA CA2805984A patent/CA2805984C/en active Active
- 2011-08-10 PL PL11760415T patent/PL2603528T3/pl unknown
- 2011-08-10 US US13/816,390 patent/US9359439B2/en active Active
2016
- 2016-07-29 JP JP2016149616A patent/JP2016185169A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP2603528B1 (en)	2016-10-12
CA2805984C (en)	2021-05-25
CN103119064B (zh)	2018-09-04
JP2013535970A (ja)	2013-09-19
WO2012020065A1 (en)	2012-02-16
BR112013003095A2 (pt)	2016-07-05
JP2016185169A (ja)	2016-10-27
DK2603528T3 (en)	2016-11-28
US20130209458A1 (en)	2013-08-15
AU2011288464B2 (en)	2015-10-29
AU2011288464A1 (en)	2013-02-14
CA2805984A1 (en)	2012-02-16
ES2605304T3 (es)	2017-03-13
JP6334166B2 (ja)	2018-05-30
BR112013003095B1 (pt)	2023-03-28
EP2603528A1 (en)	2013-06-19
PT2603528T (pt)	2016-12-01
CN103119064A (zh)	2013-05-22
US9359439B2 (en)	2016-06-07

Publication	Publication Date	Title
HRP20180952T1 (hr)	2018-07-27	Anti-dll3 antitijelo
ZA201701051B (en)	2018-05-30	Neutralizing anti-ccl20 antibodies
ZA201209004B (en)	2013-08-28	Anti-fgfr2 antibodies
GB201000467D0 (en)	2010-02-24	Antibodies
IL221371A0 (en)	2012-10-31	Anti-lrp6 antibodies
PL2581113T3 (pl)	2018-11-30	Przeciwciało anty-tim-3
PL2616489T3 (pl)	2017-07-31	Przeciwciało anty-huTNFR1
HK1182625A1 (en)	2013-12-06	Bispecific antibodies
ZA201208290B (en)	2013-07-31	Anti-erbb3 antibodies
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
IL220404A (en)	2017-05-29	Antiseptic antibodies
IL225667A0 (en)	2013-06-27	A new antigen
HK1194388A1 (zh)	2014-10-17	抗缺刻蛋白抗體
GB201020738D0 (en)	2011-01-19	Antibodies
PL2603528T3 (pl)	2017-07-31	Przeciwciała Fab-glikozylowane
GB201002238D0 (en)	2010-03-31	Antibodies
ZA201302459B (en)	2014-01-29	Antibodies
GB201007957D0 (en)	2010-06-30	Antibody
EP2714074A4 (en)	2015-04-22	ANTIBODIES AGAINST EMR1
GB201020751D0 (en)	2011-01-19	Antibodies
GB201005062D0 (en)	2010-05-12	Antibodies
GB201017780D0 (en)	2010-12-01	Antibody
IL226635B (en)	2019-09-26	Human anti-sod1 antibodies